Urologic Oncology Articles

Researcher Hopes Vaccines Can Improve Immunotherapy Outcomes in RCC
Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.
Robotic Surgery Is Milestone Advancement for Prostate Cancer Treatment
David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.
PD-1/VEGF Combos a Next Step for RCC Treatment

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

Rini Stresses Axitinib Remains Significant in RCC
The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.
Prostate Cancer Treatment Rates Drop Following Changes in Screening Recommendations
A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.
Researcher Discusses Optimal Sequencing in Advanced RCC
Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward. 
Expert Discusses Docetaxel's Continued Significance in Prostate Cancer
William Oh, MD, discusses the continued significant of docetaxel in advanced prostate cancer.
Challenges Persist in Deploying ADT in Prostate Cancer

In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.

The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Dual Androgen Blockade Ineffective After Enzalutamide in mCRPC
Adding enzalutamide to abiraterone acetate failed to improve progression-free survival versus abiraterone alone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.
Publication Bottom Border
Border Publication